Related Experiment Video
Updated: May 11, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
[Changes of protein expression in HepG2 cells with CDK2 RNA interference]
Jin Shang1, Zhenyu Wang, Junzao Li
1Department of Dermatology, Frist Affiliated Hospital, Baotou Medical College, Baotou Public Security Bureau, China. shangjin.8299@yahoo.com.cn
Objective:
To investigate the effects of stable transfection of CDK2 siRNA on biological activities and nuclear proteins of human hepatocellular carcinoma HepG2 cells.
Methods:
HepG2 cells were transfected with the eukaryotic expression vector of P(Genesil-1-CDK2); via RNA interference and selected for the ones with stable transfection. We observed the changes in the cell growth curve and cell cycle. The mRNA contents of CDK2 and differentially expressed nucleoproteins were detected and analyzed by RT-PCR and two-dimensional (2D) electrophoresis-mass spectrum (MS)-database, respectively. Western blotting were used to confirm the differential protein expressions.
Results:
Compared with P(HK-siRNA);-HepG2 and untransfected groups, the proliferation of HepG2 cells in P(CDK2-siRNA);-HepG2 group was significantly inhibited (P<0.01), and the expression of CDK2 mRNA significantly decreased in P(CDK2-siRNA);-HepG2 group. Four proteins not expressed in P(CDK2-siRNA);-HepG2 cells were detected by 2D electrophoresis-MS, and they were further confirmed by Western blotting.
Conclusion:
CDK2 siRNA significantly suppressed CDK2 mRNA expression and the proliferation of HepG2 cells, four proteins not expressed in p(CDK2-siRNA);-HepG2 cells are similar to ribosomal protein S12, β-actin, zine finger 276 and chaperonin 10 related protein.
Insights
CDK2 siRNA significantly inhibited hepatocellular carcinoma HepG2 cell proliferation and CDK2 mRNA expression. Four novel proteins were identified as not expressed in treated cells, impacting cell biology.
Area of Science:
- Molecular Biology
- Cancer Research
- Biochemistry
Context:
- Hepatocellular carcinoma (HCC) is a significant global health concern.
- Cyclin-dependent kinase 2 (CDK2) plays a crucial role in cell cycle regulation and cancer progression.
- Targeting CDK2 is a potential therapeutic strategy for HCC.
Purpose:
- To investigate the effects of stable transfection of CDK2 siRNA on biological activities and nuclear proteins of human hepatocellular carcinoma HepG2 cells.
- To assess the impact of CDK2 inhibition on cell proliferation, cell cycle, and protein expression profiles.
Summary:
- Stable transfection of CDK2 siRNA in HepG2 cells significantly inhibited cell proliferation and reduced CDK2 mRNA expression.
- Two-dimensional electrophoresis-mass spectrometry identified four proteins (ribosomal protein S12, β-actin, zinc finger 276, and chaperonin 10 related protein) that were not expressed in CDK2 siRNA-treated cells.
- Western blotting confirmed the differential expression of these proteins.
Impact:
- CDK2 siRNA demonstrates potential as a therapeutic agent for hepatocellular carcinoma by suppressing tumor growth.
- Identification of novel proteins affected by CDK2 inhibition provides insights into HCC pathogenesis.
- This study contributes to understanding the molecular mechanisms underlying HCC and informs the development of targeted therapies.
Related Concept Videos
Inhibition of Cdk Activity
Inhibition of CDK Activity
Positive Regulator Molecules
Negative Regulator Molecules

